Results 121 to 130 of about 9,624 (181)

Immune Checkpoint Inhibitors in Clear Cell Renal Cell Carcinoma (ccRCC)

Renal cell carcinoma (RCC) accounts for about 403,000 new cases and 175,000 deaths worldwide each year. Clear cell RCC (ccRCC), the most prevalent subtype, is often driven by genetic mutations, such as VHL inactivation, leading to angiogenesis and immune
Anna Gluba-Sagr, Rysz, Jacek, Franczyk, Beata, Gluba-Sagr, Anna, Janusz Ławiński, Beata Franczyk, Ławiński, Janusz, Jacek Rysz   +7 more
core   +1 more source

Distribution of GRP78 staining intensity in tumor associated adipose tissue among benign tumor and different ccRCC grades.

, 2019
Compared with grade 2 (N = 25) and grade 3 (N = 21) ccRCC, grade 4 ccRCC (N = 13) and benign tumor (N = 7) exhibited a lower expression of GRP78, as indicated by greater average grey values. Abbreviation: ccRCC, clear cell renal cell carcinoma.
Sharon Juliet Del Vecchio (6239654), Robert J. Ellis (668685), David W. Johnson (221347), Glenda C. Gobe (3630025), David A. Vesey (3234039), Armando Teixeira-Pinto (101747), Michael A. McGuckin (128370), Yeoungjee Cho (6239657), Kunyu Shen (6239651)   +8 more
core   +1 more source

Altered ammonia metabolism in ccRCC [PDF]

Nature Reviews Nephrology, 2018
openaire   +2 more sources

Efficacy of 8-chloroadenosine in ccRCC cell lines.

, 2015
a. ccRCC cell lines treated with 20 μM or 80 μM 8-chloroadenosine for 7 days. b. Cell cycle analysis of ccRCC cell lines treated with 40 μM 8-chloroadenosine for 48 hours. c. IC50 values of ccRCC cell lines calculated in Calcusyn software.
Amado J. Zurita (270090), You-Hong Fan (789032), Babita Saigal (789034), Varsha Gandhi (147452), John V. Heymach (160316), Alper Y. Kearney (789031), Uma Giri (789033)   +6 more
core   +1 more source

Prognostic Value and Immunological Role of POP7 in Clear Cell Renal Cell Carcinoma

Pharmacogenomics and Personalized Medicine
Ning Lou,1,* Xiangui Meng,2,* Tiexi Yu,2,* Weiquan Li,2,* Xin Lv,3,* Weiwei Han,1 Wen Xiao,2 Ying Shi2 1Department of Urology, The Central Hospital of Wuhan, Tongji Medical College, Huazhong University of Science and Technology, Wuhan,
Lou N, Meng X, Yu T, Li W, Lv X, Han W, Xiao W, Shi Y   +7 more
doaj  

GAMT facilitates tumor progression via inhibiting p53 in clear cell renal cell carcinoma

Biology Direct
Background Clear cell renal cell carcinoma (ccRCC) is the most common type of RCC. Even though the targeted drugs for the treatment of ccRCC have a certain therapeutic effect, due to the problem of drug resistance, the search for new targets for targeted
Bin Zheng, Kan Liu, Ji Feng, Qing Ouyang, Tongyu Jia, Yaohui Wang, Shuo Tian, Xinran Chen, Tianwei Cai, Lequan Wen, Xu Zhang, Xiubin Li, Xin Ma   +12 more
doaj   +1 more source

Exploring the value of arterial spin labeling and six diffusion MRI models in differentiating solid benign and malignant renal tumors

European Radiology Experimental
Objective To explore the value of three-dimensional arterial spin labeling (ASL) and six diffusion magnetic resonance imaging (MRI) models in differentiating solid benign and malignant renal tumors.
Mengmeng Gao, Shichao Li, Guanjie Yuan, Weinuo Qu, Kangwen He, Zhouyan Liao, Ting Yin, Wei Chen, Qian Chu, Zhen Li   +9 more
doaj   +1 more source

A central anti-oncogenic pathway in ccRCC [PDF]

Nature Reviews Nephrology, 2018
openaire   +2 more sources

Identification of novel biomarkers to distinguish clear cell and non-clear cell renal cell carcinoma using bioinformatics and machine learning.

PLoS ONE
Renal cell carcinoma (RCC), accounting for 90% of all kidney cancer, is categorized into clear cell RCC (ccRCC) and non-clear cell RCC (non-ccRCC) for treatment based on the current NCCN Guidelines.
Chanita Panwoon, Wunchana Seubwai, Malinee Thanee, Sakkarn Sangkhamanon   +3 more
doaj   +1 more source

Pivotal biomarker expression and drug screening in advanced ccRCC [PDF]

Clinical and Translational Medicine, 2020
Wen Xiao, Ke Chen, Xiaoping Zhang
openaire   +3 more sources